CEO: Vince Burgess

Advent Contact: Shahzad Malik

Best-in-class mapping system for atrial fibrillation ablation procedures

The AcQMap™ is a breakthrough technology which integrates ultrasound and a proprietary mapping platform to provide a map of complex arrythmias with unprecedented accuracy and in real time to guide ablation therapy. The AcQMap™ received CE mark in May 2016.

Advent first invested in the Series A in 2011. Acutus most recently completed a $75m Series C financing in March 2016.

Acutus Medical® Receives FDA Clearance for Advanced Cardiac Mapping Technology for Complex Arrhythmias

Acutus Medical Announces Pricing of Initial Public Offering